UK's AMRC Licenses Shionogi Superbug Therapy

As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.

Butterflies
A UK-Japan alliance takes flight to tackle superbug • Source: Shutterstock

The AMR Centre (AMRC), established three years as part of the UK’s response to the global threat from antimicrobial resistance, has pulled off something of a coup by bagging the rights to a promising novel monoclonal antibody from Japan's Shionogi & Co. Ltd..

The therapy, codenamed COT-143, is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant superbug...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category